Putin is only stopped because of the weapons we have given Ukraine and the constant updated recon.... without US & NATO the war is already over.
I bought FL because I think Marry Dillion did a bang up job at ULTA. If I lose cash on Foot Licker, I will trade another account making up the losses and average down like the dummy I am!
Bausch Health up 10% after FDA issues draft guidance on generic Xifaxan 14:30 BHC Shares of Bausch Health are rising after the FDA issued draft guidance on Rifaximin. In terms of establishing bioequivalence, the draft guidance gives companies two options: Option 1, which involves four in vivo bioequivalence studies with pharmacokinetic endpoints and in vitro bioequivalence studies of comparative dissolution, and Option 2, which involves in vivo bioequivalence studies with pharmacokinetic endpoints, in vitro bioequivalence studies of comparative dissolution, and in vivo bioequivalence studies with clinical endpoints, a document posted to the site of the FDA explains. Following the draft guidance publication, Evercore ISI analyst Umer Raffat said the new product specific guidance for generic Xifaxan included a "key change," namely that the new guidance no longer grants a waiver of in vivo testing for the 550 mg strength based on 200 mg testing. By doing this, the FDA added "an extra layer hurdle for generics to jump through," according to Raffat, who adds that generic 550 mg "is really what matters" given that the 550 mg dose is "where 99% of the Xifaxan volume lies." Raffat has an In Line rating on Bausch Health, the maker of branded Xifaxan. In afternoon trading, shares of Bausch Health are up 66c, or about 10%, to $7.63. Reference Link Show Related Items >>
You can always re buy. Citi cuts Foot Locker target, opens 'negative catalyst watch' 07:02 FL Citi analyst Paul Lejuez lowered the firm's price target on Foot Locker to $33 from $38 and keeps a Neutral rating on the shares. He also opened a "negative catalyst watch" on the shares into the November 18 results. The analyst anticipates a modest earnings beat in Q3 but says the focus will be on Q4 guidance given Adidas' decision to cut ties with the Yeezy brand. Yeezy's rivaled the iconic Jordan Retros in recent years in terms of pricing and launch excitement, Lejuez tells investors in a research note. With Foot Locker's reduced allocation of high-heat Nike product, the company has increasingly leaned into its partnership with Adidas to offset the loss of Nike, says the analyst. His checks suggest there will be no Yeezy product in stores in Q4, which he believes will be a "significant headwind" to Q4 comps.
You’re probably right, NKE’s was pretty bad with a ton of inventory build. I made enough on the NVDA put side(Dam they hit $3.20!!!!) to cover for any screw ups(Not counting the $160C side).
More and more Ted I have learned not to be a hero. I tended to let my personal views of directional calls shade my common sense in the past. I would hold something because a new CEO, or it's a good idea... Capri is a good example no matter how good an idea and how many wedding dresses Michael Koors sold and how many times they beat their number it didn't matter, the sector weakness took them down. And me down. So now I dip out and get back in without shame on some names. (especially RH it seems)
Update I've gotten a few emails--- there is an end of qtr thing happening and I agree it's distressing we have not turned positive. If we open down tomorrow and break the lows I sold at.... It is possible The Lizard king screwed up and should of held out. My initial thought was 3,800+ level but I got jumpy today-- S&P 500 (^GSPC) SNP - SNP Real Time Price. Currency in USD Add to watchlist 3,925.92-32.87(-0.83%)<--------------- As of 03:29PM EST. .